Table 3.
Variable | Number | % |
---|---|---|
Local manifestations | ||
Pain (n=364) | 348 | 95.6 |
Edema (n=363) | 297 | 81.8 |
Ecchymosis (n=358) | 21 | 5.9 |
Systemic manifestations | ||
Neuroparalysis (n=376) | 83 | 22.1 |
Myolysis (n=378) | 61 | 16.1 |
Bleeding (n=375) | 34 | 9.1 |
Vomiting/diarrhea (n=374) | 31 | 8.3 |
Clotting time (n=113) | ||
Normal | 50 | 44.2 |
Prolonged | 63 | 55.8 |
Severity grade on admission* (n=381; 96.2%) | ||
Mild | 151 | 39.6 |
Moderate | 170 | 44.6 |
Severe | 60 | 15.7 |
Antivenom administration (n=381; 96.2%) | ||
Underdosage | 155 | 40.7 |
As recommended | 226 | 59.3 |
Local complications | ||
Secondary infection (n=345) | 11 | 3.2 |
Necrosis (n=343) | 4 | 1.2 |
Compartment syndrome (n=344) | 2 | 0.6 |
Functional loss (n=343) | 3 | 0.9 |
Amputation (n=343) | 1 | 0.3 |
Systemic complications | ||
Acute renal failure (n=336) | 33 | 9.8 |
Respiratory failure (n=335) | 8 | 2.4 |
Sepsis (n=335) | 2 | 0.6 |
Shock (n=334) | 5 | 1.5 |
Death (n=350) | ||
Yes | 4 | 1.1 |
*According to Brazilian Ministry of Health guideline (139).